Marc Beer: The New Chairman of the board at Lumenxt Inc.

LumeN XT, Inc. is a privately owned company that is focused on developing surgical illumination products necessary when carrying out minimally invasive surgeries; less pain, fewer days in the hospital and few complications. Recently, Marc Beer was appointed as the chairman of the board. Marc Beer has over twenty-five years’ experience in biotechnology and pharmaceuticals.


After nomination, Marc Beer said that he was proud to be working with such dedicated surgeons and engineers who have contributed a lot to the surgical illumination department, in LumeN XT. Marc believes that LumeN XT platform will increase the number of minimally invasive surgeries in the country. To enhance visualization and flexibility while carrying out the operations, surgeons have confirmed that they use targeted illumination. This technology does less damage as compared to the traditional methods that surgeons used.


The Co-founder of LumeN XT, Paul Rhyne, gushed about Marc Beer’s high- level successes. Several companies experienced much growth under his leadership. Paul is certain that the new chairman will lead the company to a greater height, more profitability, hence the vast growth of the company. This LumeN XT improved illumination platform is used as a mechanism to reduce heat while performing surgeries. It provides cheaper disposable options and better surgical precision. All these are enhanced through visualization.


Mr. Beer is also the founder, chairman and the Chief Executive Officer of Renovia, Inc. The company’s main goal is to create and deliver the best digital devices for therapy and diagnosis of pelvic disorders in women. The company was founded in the year 2016, August. Before Renovia, Marc had founded a biopharmaceutical company: Minerva Neurosciences Inc. He was the chairman of the company. Minerva Neurosciences Inc. main focus was to develop products that would be used to treat Central Nervous System disorder (CNS). Other than that, Minerva has developed innovative therapeutic drugs for five diseases: schizophrenia, mood disorders, depressive disorders, Parkinson’s Disease, and even insomnia. Learn more:


There’s no telling where the medical field would be without Marc Beer. He has had many medical breakthroughs. Over the years, Marc has held top leadership roles in biopharmaceutical departments. In most of them, he was in charge of commercial launches. He would also address rare disease globally, global growth, acquisitions, initial public offerings (IPOs), just to mention a few. Mr. Beer is also the founder of Aegerion Pharmaceuticals, Inc., and he acted as its chief executive officer before joining Minerva. Aegerion Pharmaceuticals is a company that develops innovative therapies for patients suffering from debilitating rare diseases. Other top positions Marc had included: Chairman of Good Start Genetics, Inc., CEO of ViaCell, a member of the board of directors of Erytech Pharma and the Executive Vice President of Global Marketing at Genzyme. Marc Beer recognized his calling and passion and he is working on it. Follow Marc Beer on LinkedIn